by | Jun 30, 2025 | Lupus Foundation of America
When Jason first joined the Man Cave, a virtual Lupus Foundation of America (LFA) group for men living with lupus, his camera and mic were off, he didn’t participate in the discussion and he left early after 30 minutes.It was disheartening to see for Kevin Vaughn, a...
by | Jun 26, 2025 | Lupus Foundation of America
This year, the Lupus Foundation of America (LFA) is pleased to announce two recipients of grants supporting pediatric lupus research. This year’s recipients are Nayimisha Balmuri, MD, Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine, who...
by | Jun 25, 2025 | Lupus Foundation of America, News & Events
The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active lupus nephritis (LN, lupus-related kidney disease) who are...
by | Jun 24, 2025 | Lupus Foundation of America
The Lupus Foundation of America continues to lead advocacy efforts to protect and strengthen funding for the National Institutes of Health (NIH), which is the largest funder of lupus research. Recently, we joined with 100 patient, research and health professional...
by | Jun 20, 2025 | Lupus Foundation of America, News & Events
Researchers from EMD Serono and global collaborators shared promising results from Cohort B of the phase II trial of the WILLOW study, evaluating the safety and efficacy of enpatoran, a first-in-class oral toll-like receptor 7 and 8 (TLR7/8) inhibitor, in people with...
by | Jun 6, 2025 | Lupus Foundation of America, News & Events
Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage BCMAxCD3 bispecific T cell engager. The agreement allows Cullinan to explore the development of the therapy in autoimmune diseases, like lupus....
